Individualizing Care On-Demand

  IndividualizingCare2015_Theme_Banner_v4.jpg

IndCare2015_OnDemand_button_register

About the Program:

Program Overview:

Antiretroviral therapy (ART) has evolved considerably over the past three decades. With many antiretroviral (ARV) drugs, combinations, and classes available, health care providers have multiple choices regarding ARV therapy. While these choices provide clinicians with many useful options, they also lead to challenges. One of the biggest challenges for clinicians is individualizing the care of HIV-positive patients and understanding when certain ARV therapies and strategies are appropriate, and when they are not. Numerous studies have shown that ARV therapy must be tailored to the individual patient and his or her abilities and diverse needs. A "cookie-cutter" or "one size fits all" approach can lead to poor outcomes, with higher rates of virologic failure and ARV-related toxicities. With the wealth of choices available, plus rapidly changing treatment guidelines and an aging population, the challenge for health care providers remains weighing the relative benefits and risks of each ARV and ARV combination and creating an appropriate ARV regimen that is potent, tolerable, safe, free of drug-drug interactions, convenient, and durable. The ideal utilization of the individualized approach to ART consists of a combined approach using knowledge of drug, virus, and patient information to guide a personalized prescription. However, many clinicians have difficulty keeping up with new clinical studies and assessing when certain ARV therapies are indicated or contraindicated.

This CME On-Demand internet symposium is designed to address the challenge of individualizing HIV care and features HIV thought leaders describing and discussing current treatment guidelines and recent research findings, including conference reports, and then explain how to apply them to the optimal care of a wide variety of HIV patients, including HIV/HCV co-infected patients. Along with this online program, there is a series of live in-clinic meetings that are designed to bring this important and complex information to health care providers nationwide to support the optimal and personalized treatment of people with HIV. A list of current dates and locations can be found on the program homepage and will be updated regularly with new dates/locations.

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the care of patients with HIV-infection. It is tuition-free and there are no prerequisites.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Explain the importance of individualizing ARV therapy
  • Individualize ARV therapy to improve treatment outcomes
  • Employ the skills needed to gather knowledge regarding the patient and establish a trusting relationship that furthers the exchange of information between clinician and patient needed to accomplish individualization of care
  • Utilize the concepts important in individualizing ARV therapy including considering and weighing the characteristics of the ARV therapy options available and applying this knowledge to the characteristics of the individual patient to arrive at the optimal choice of ARV therapy for that individual

Release Date: June 5, 2015

Expiration Date: June 5, 2016

Estimated time to complete the On-Demand Internet Symposium: 2 hours, 15 minutes 

Media: Internet

Back to Top

Faculty:

Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC

Wilbert Jordan, MD
Medical Director,
Charles Drew Medical Center
Los Angeles, California  

Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois

Pablo Tebas, MD
Professor of Medicine,
Hospital of the University of Pennsylvania
Director, Aduld AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the Univerisity of Pennsylvania
Philadelphia, Pennsylvania

Back to Top 

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation:

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. the Annenberg Center for Health Sciences at Eisenhower is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:  

Richard Elion, MD

  • Consulting Fees: BMS, Gilead, ViiV Healthcare
  • Fees for Non-CME/CE Services: BMS, Gilead, Janssen, Merck, ViiV Healthcare
  • Contracted Research: Abbvie, BMS, Gilead, Merck, ViiV

Wilbert Jordan, MD

  • Consulting Fees: Gilead, BMS, Janssen

Renslow Sherer, MD

  • No real or apparent conflicts to disclose

Pablo Tebas, MD

  • Consulting Fees: Merck, GSK, Janssen, Gilead, AstraZeneca
  • Contracted Research: Merck, GSK, Janssen, Gilead, Vertex, BMS, ViiV, Barvaria
  • Other:DSMB -Cytheris
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Charles E. Willis MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Prices, Registration Database Administrator and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower, have no relevant commercial relationships to disclose.


Instruction for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period, June 5, 2015 through June 5, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10757.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.    

Back to Top

 

 

 

  Annenberg_Centered_logo.jpg

PIM_small

VE logo 300px 

  Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. in collaboration with Postgraduate Institute for Medicine.

This activity is supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products, LP 

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Prepare to print

Share this page:

Get link code to this page     


Back to Top